Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1.
Am J Kidney Dis
; 82(1): 113-116, 2023 07.
Article
en En
| MEDLINE
| ID: mdl-36693470
ABSTRACT
Primary hyperoxaluria type 1 is a rare cause of kidney failure. Stiripentol, an inhibitor of lactate dehydrogenase A, and lumasiran, a small interfering RNA targeting glycolate oxidase, have been proposed as therapeutic options, but clinical data are scarce, especially in adults and transplanted patients. We describe the case of a 51-year-old patient with a biopsy-proven recurrence of oxalate nephropathy after a kidney-only transplantation. He received stiripentol and lumasiran without adverse events. Fourteen months after transplantation, graft function, serum, and urinary oxalate levels have remained stable, and kidney biopsy showed a complete regression of oxalate crystals. Further studies are needed to assess whether this strategy is effective and could replace liver-kidney transplantation.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Hiperoxaluria
/
Hiperoxaluria Primaria
/
Trasplante de Riñón
/
Insuficiencia Renal
Tipo de estudio:
Etiology_studies
Límite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Kidney Dis
Año:
2023
Tipo del documento:
Article
País de afiliación:
Francia